Company news

Relmada Therapeutics, Inc. news in 2021

Relmada Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

December 21, 2021

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 13, 2021

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

December 7, 2021

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

December 7, 2021

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 10, 2021

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 9, 2021

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

July 26, 2021

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

July 19, 2021

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting

May 25, 2021

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 11, 2021

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

May 5, 2021

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

April 30, 2021

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

April 28, 2021

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

April 27, 2021

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

April 26, 2021

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

March 31, 2021

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

March 22, 2021

Calls in 2021

Decks in 2021